Further, SER140 exceeded the maximal effect of anakinra (a recombinant, nonglycosylated version of human IL-1R antagonist) in averting IL-1β-induced apoptosis in rat pancreatic islets [17] and is currently being evaluated for treatment of T2D. Here, IL1B is linked to type 2 diabetes mellitus.